Status:
COMPLETED
Interferon Alpha Therapy for Cervical CINI and HPV Infection
Lead Sponsor:
Mongolian National University of Medical Sciences
Collaborating Sponsors:
Mongolian National Cancer Center
Conditions:
Cervical Dysplasia
HPV Infection
Eligibility:
FEMALE
20-40 years
Phase:
PHASE1
Brief Summary
Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the medical care service is not sufficient. In 2000, Mongolian government has developed and implemented the millenniu...
Detailed Description
The purpose of the study is to evaluate the efficacy of interferon treatment for HPV infection shedding and early CIN change. Women aging from 20-40 years will be enrolled in the study. The treatment...
Eligibility Criteria
Inclusion
- Pap smear LSIL
- HPV infection positive
- No anti-viral treatment in 2 weeks before treatment
Exclusion
- No consent has obtained
- Anti-viral treatment in 2 weeks
- Breastfeeding or pregnant
Key Trial Info
Start Date :
November 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06137950
Start Date
November 7 2023
End Date
March 31 2025
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center
Ulaanbaatar, Mongolia, 17011